FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and immunology. There are presented: a method for tumour cell growth inhibition in an individual and a method for immune response enhancement in an individual involving the introduction of a PD-1 monoclonal antibody and a CTLA-4 10D1 monoclonal antibody to the individual. The PD-1 monoclonal antibody has the following properties: it binds to human PD-1 having the value KD equal to 1×10-8 M or less; however it binds neither to human CD28, nor to CTLA-4, nor to ICOS; it is able to enhance the T-cell proliferation in the mixed lymphocyte reaction (MLR) analysis; it is able to enhance the gamma interferon production in the MLR analysis; it is able to enhance the interleukine-2 (IL-2) secretion in the MLR analysis.
EFFECT: invention provides a synergic effect when using the above antibodies in a combination.
4 cl, 54 dwg, 7 tbl, 25 ex
| Title |
Year |
Author |
Number |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2013 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanyuj
- Selbi Mark Dzh.
- Chen Bin
- Kardarelli Zhozefin M.
|
RU2599417C2 |
| HUMAN MONOCLONAL ANTIBODIES TO THE PROTEIN OF PROGRAMMED DEATH 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2016 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanyuj
- Selbi Mark Dzh.
- Chen Bin
- Kardarelli Zhozefin M.
|
RU2732924C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2006 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanjuj
- Selbi Mark Dzh.
- Chehn' Bin
- Kardarelli Zhozefin M.
|
RU2406760C2 |
| PD-1 ANTIBODIES AND USE THEREOF |
2016 |
|
RU2722451C1 |
| ANTIBODIES DIRECTED TO PROTEIN OF PROGRAMMED DEATH OF CELL-1 (PD-1) |
2014 |
- King Devid Dzh.
- Keri Merilin
|
RU2723050C2 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN |
2016 |
- Zheng, Yong
- Li, Jing
- Gololobov, Gennady
- Zhang, Xinhua
- Yang, Baotian
- Tang, Zhewei
- Li, Dong
- Xu, Jianqing
- Wang, Zhuozhi
|
RU2757316C2 |
| PD-1 BINDING ANTIBODIES AND METHODS OF THEIR USE |
2019 |
|
RU2812280C1 |
| ANTIBODIES BINDING TO PD-1 AND THEIR APPLICATIONS |
2019 |
|
RU2773758C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE |
2018 |
- Yang, Yi
- Xie, Jingshu
- Dong, Chunyan
- Yang, Fang
- Lu, Chengyuan
- Cheng, Xiaodong
- Shen, Yuelei
- Ni, Jian
- Guo, Yanan
- Chen, Yunyun
|
RU2788616C2 |
| ANTI-PD-1 ANTIBODIES |
2015 |
- Zha Jiping
- Sun Ziyong
- Qiu Junzhuan
|
RU2711141C2 |
